5-HT1A receptor subtype agonist

Abstract

The present invention relates to a method of treating a patient suffering from a disorder of the central nervous system associated with 5-HT 1A receptor subtype, comprising as an active ingredient a carbostyril derivative or a salt thereof represented by the formula (1) wherein the carbon-carbon bond between 3- and 4-positions in the carbostyril skeleton is a single or a double bond.

1 . A method of treating a patient suffering from a disorder-of the central nervous system associated with 5-HT 1A  receptor subtype, selected from
 (i) bipolar I disorder with most recent hypomanic, manic, mixed, depressed or unspecified episode, and   (ii) bipolar II disorder with recurrent major depressive episodes with hypomanic episodes, and cyclothymic disorder,   which comprises administering to said patient a therapeutically effective amount of a carbostyril compound of formula (1), or a pharmaceutically acceptable salt or solvate thereof, wherein said patient is a mammal:   
       
         
           
           
               
               
           
         
         wherein the carbon-carbon bond between 3- and 4-positions in the carbostyril skeleton is a single or a double bond. 
       
     
     
         2 . The method of  claim 1 , wherein the disorder is bipolar I disorder as defined in (i). 
     
     
         3 . The method of  claim 1 , wherein the disorder is bipolar II disorder as defined in (ii). 
     
     
         4 . (canceled) 
     
     
         5 . The method according to  claim 1 , wherein the carbostyril compound is
 7-{4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy}-3,4-dihydrocarbostyril.   
     
     
         6 . The method according to  claim 2 , wherein the
 7-{4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy}-3,4-dihydrocarbostyril.   
     
     
         7 . The method according to  claim 3 , wherein the carbostyril compound is 7-{4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy}-3,4-dihydrocarbostyril. 
     
     
         8 . (canceled)